A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Molecular Medicine Bookmark and Share

Molecular Medicine

The Department of Molecular Medicine of Beckman Research Institute of City of Hope  advances translational medicine through breakthroughs in basic science using chemical biology and genomic approaches. Our investigators lead cutting-edge research to determine the mechanisms underlying cancer and other serious diseases such as diabetes. The goal of the department is to customize prevention and treatment of such illnesses by developing targeted therapies for an individual’s genomic profile. Success produces more effective clinical responses to our treatments and less drug toxicity and resistance.
 
The department is composed of a carefully crafted team of experts in chemistry, biology, biochemistry and biophysics that identifies new target molecules to treat cancer, creates personalized medicines from natural products, develops bioorganic approaches for cancer therapy, and evaluates genomic markers to predict cancer risk and response to therapy. By collaborating with multidisciplinary groups that include basic, translational and clinical researchers throughout City of Hope, we transform our key findings into novel therapies that improve the quality of life for patients everywhere.
 
The department has a robust pipeline of novel, molecularly targeted therapeutics that includes engineered antibodies and small molecules. To facilitate the translation of these and other clinical candidates, the department is home to the Chemical GMP Synthesis Facility (CGSF),   which is a 3000-square-foot, state-of-the-art manufacturing facility where our small and large molecule therapeutics are prepared for phase I and II clinical trials. The CGSF plays a key role in bridging basic science and translational medicine at City of Hope and allows for more efficient and cost-effective means to translate our science into clinical practice. We are able to bring promising new therapies to the patient faster and more effectively. 

To accomplish our mission, the Molecular Medicine team uses approaches and technologies that include:
 
  • sophisticated organic synthesis and medicinal chemistry
  • high-tech protein engineering
  • functional genomics, proteomics, and microarray gene expression profiling
  • high throughput screens of plant extracts and chemical libraries
  • advanced NMR spectroscopy and computational modeling
  • state-of-the-art X-ray crystallography
  • leading-edge super-resolution microscopy
 
These activities are supported by the Drug Discovery and Structural Biology (DDSB) Core, which is also housed in the department.
 
 
Laboratory Research
 
Jacob Berlin, Ph.D. - Molecular medicine
Dr. Berlin’s research group is focused on the application of nanomaterials for the diagnosis and treatment of cancer.
 
Yuan Chen, Ph.D. - Ubiquitin-like modifications
Dr. Chen investigates post-translational modifications by ubiquitin-like proteins via a wide range of techniques that include determination of protein structures and dynamics by NMR, investigation of enzyme mechanisms by biochemical and biophysical means, and examination of the role of these modifications in response to DNA damage by cellular and molecular biology methods.
 
David Horne, Ph.D., chair  - Synthetic/medicinal chemistry
Dr. Horne’s laboratory specializes in the synthesis of complex natural products and derivatives to develop molecularly targeted agents that are less toxic and more effective in treating the unmet needs in cancer and diabetes.
 
Robert Hickey, Ph.D. - Molecular Medicine
 
Tijana Jovanovic-Talisman, Ph.D. - Super-resolution microscopy
Dr. Jovanovic-Talisman’s research group employs novel, quantitative imaging techniques and nano-biological assays to investigate biological mechanisms and advance therapeutics.

Theodore G. Krontiris, M.D., Ph.D. - Genetic risk and disease
Dr. Krontiris and his group examine the relationship between certain unstable regions of the genome, known as hypervariable minisatellites, and cancer risk.

John Termini, Ph.D. - Molecular medicine
Members of Dr. Termini's laboratory are interested in understanding the role of DNA adducts in cancer. This encompasses mechanisms of formation, structure elucidation of novel adducts, quantitative determination in vivo, functional implications, and removal/repair.

John Williams, Ph.D. - X-ray crystallography
Dr. Williams specializes in the use of X-ray crystallography to study protein-protein and drug-protein interactions for the design of novel therapeutic agents for the treatment of cancer.
 

Molecular Medicine Faculty

Molecular Medicine

Molecular Medicine

The Department of Molecular Medicine of Beckman Research Institute of City of Hope  advances translational medicine through breakthroughs in basic science using chemical biology and genomic approaches. Our investigators lead cutting-edge research to determine the mechanisms underlying cancer and other serious diseases such as diabetes. The goal of the department is to customize prevention and treatment of such illnesses by developing targeted therapies for an individual’s genomic profile. Success produces more effective clinical responses to our treatments and less drug toxicity and resistance.
 
The department is composed of a carefully crafted team of experts in chemistry, biology, biochemistry and biophysics that identifies new target molecules to treat cancer, creates personalized medicines from natural products, develops bioorganic approaches for cancer therapy, and evaluates genomic markers to predict cancer risk and response to therapy. By collaborating with multidisciplinary groups that include basic, translational and clinical researchers throughout City of Hope, we transform our key findings into novel therapies that improve the quality of life for patients everywhere.
 
The department has a robust pipeline of novel, molecularly targeted therapeutics that includes engineered antibodies and small molecules. To facilitate the translation of these and other clinical candidates, the department is home to the Chemical GMP Synthesis Facility (CGSF),   which is a 3000-square-foot, state-of-the-art manufacturing facility where our small and large molecule therapeutics are prepared for phase I and II clinical trials. The CGSF plays a key role in bridging basic science and translational medicine at City of Hope and allows for more efficient and cost-effective means to translate our science into clinical practice. We are able to bring promising new therapies to the patient faster and more effectively. 

To accomplish our mission, the Molecular Medicine team uses approaches and technologies that include:
 
  • sophisticated organic synthesis and medicinal chemistry
  • high-tech protein engineering
  • functional genomics, proteomics, and microarray gene expression profiling
  • high throughput screens of plant extracts and chemical libraries
  • advanced NMR spectroscopy and computational modeling
  • state-of-the-art X-ray crystallography
  • leading-edge super-resolution microscopy
 
These activities are supported by the Drug Discovery and Structural Biology (DDSB) Core, which is also housed in the department.
 
 
Laboratory Research
 
Jacob Berlin, Ph.D. - Molecular medicine
Dr. Berlin’s research group is focused on the application of nanomaterials for the diagnosis and treatment of cancer.
 
Yuan Chen, Ph.D. - Ubiquitin-like modifications
Dr. Chen investigates post-translational modifications by ubiquitin-like proteins via a wide range of techniques that include determination of protein structures and dynamics by NMR, investigation of enzyme mechanisms by biochemical and biophysical means, and examination of the role of these modifications in response to DNA damage by cellular and molecular biology methods.
 
David Horne, Ph.D., chair  - Synthetic/medicinal chemistry
Dr. Horne’s laboratory specializes in the synthesis of complex natural products and derivatives to develop molecularly targeted agents that are less toxic and more effective in treating the unmet needs in cancer and diabetes.
 
Robert Hickey, Ph.D. - Molecular Medicine
 
Tijana Jovanovic-Talisman, Ph.D. - Super-resolution microscopy
Dr. Jovanovic-Talisman’s research group employs novel, quantitative imaging techniques and nano-biological assays to investigate biological mechanisms and advance therapeutics.

Theodore G. Krontiris, M.D., Ph.D. - Genetic risk and disease
Dr. Krontiris and his group examine the relationship between certain unstable regions of the genome, known as hypervariable minisatellites, and cancer risk.

John Termini, Ph.D. - Molecular medicine
Members of Dr. Termini's laboratory are interested in understanding the role of DNA adducts in cancer. This encompasses mechanisms of formation, structure elucidation of novel adducts, quantitative determination in vivo, functional implications, and removal/repair.

John Williams, Ph.D. - X-ray crystallography
Dr. Williams specializes in the use of X-ray crystallography to study protein-protein and drug-protein interactions for the design of novel therapeutic agents for the treatment of cancer.
 

Molecular Medicine Faculty

Molecular Medicine Faculty

Overview
Beckman Research Institute of City of Hope is responsible for fundamentally expanding the world’s understanding of how biology affects diseases such as cancer, HIV/AIDS and diabetes.
 
 
Research Departments/Divisions

City of Hope is a leader in translational research - integrating basic science, clinical research and patient care.
 

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

City of Hope’s Irell & Manella Graduate School of Biological Sciences equips students with the skills and strategies to transform the future of modern medicine.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 


NEWS & UPDATES
  • The outlook and length of survival has not changed much in the past 25 years for patients suffering from an aggressive form of pancreatic cancer known as pancreatic ductal adenocarcinoma (PDAC). These patients still have few options for therapy; currently available therapies are generally toxic and do not incre...
  • “With bladder cancer, the majority of patients that I see can be cured,” said urologist Kevin Chan, M.D., head of reconstructive urology at City of Hope. “The challenge is to get patients the same quality of life that they had before surgery.” To meet this challenge, Chan and the urologic team at City of Hope [...
  • Already pioneers in the use of immunotherapy, City of Hope researchers are now testing the bold approach to cancer treatment against one of medicine’s biggest challenges: brain cancer. This month, they will launch a clinical trial using patients’ own modified T cells to fight advanced brain tumors. One of but a...
  • Brain cancer may be one of the most-frightening diagnoses people can receive, striking at the very center of who we are as individuals. Further, it often develops over time, causing no symptoms until it’s already advanced. Listen to City of Hope Radio as Behnam Badie, M.D., director of the Brain Tumor Pro...
  • The whole is greater than the sum of its parts. It takes a village. No man is an island. Choose your aphorism: It’s a simple truth that collaboration usually is better than isolation. That’s especially true when you’re trying to introduce healthful habits and deliver health care to people at risk of disease and...
  • When Maryland Governor Larry Hogan announced earlier this week that he has the most common form of non-Hodgkin lymphoma, he was giving voice to the experience of more than 71,000 Americans each year. The announcement came with Hogan’s promise to stay in office while undergoing aggressive treatment for the...
  • The spine can be affected by many different kinds of tumors. Malignant, or cancerous, tumors can arise within the spine itself. Secondary spinal tumors, which are actually much more common, begin as cancers in another part of the body, such as the breast and prostate, and then spread, or metastasize, to the spi...
  • Although most cancer occurs in older adults, the bulk of cancer research doesn’t focus on this vulnerable and fast-growing population. City of Hope and its Cancer and Aging Research Team aim to change that, and they’re getting a significant boost from Professional Practice Leader Peggy Burhenn, R.N....
  • Liz Graef-Larcher’s first brain tumor was discovered by accident six years ago. The then-48-year-old with a long history of sinus problems and headaches had been sent for an MRI, and the scan found a lesion in her brain called a meningioma – a tumor that arises in the meninges, the layers of tissue that cover a...
  • The colon and rectum are parts of the body’s gastrointestinal system, also called the digestive tract. After food is digested in the stomach and nutrients are absorbed in the small intestine, the remaining material moves down into the lower large intestine (colon) where water and nutrients are absorbed. The low...
  • If there is one truism about hospital stays it is that patients want to get out. For many, however, the joy of being discharged is tempered by the unexpected challenges that recovery in a new setting may pose. Even with professional help, the quality of care and treatment that patients receive at City of Hope [...
  • Jana Portnow, M.D., associate director of the Brain Tumor Program at City of Hope, didn’t expect to specialize in treating brain tumors. But, early in her career, she undertook a year of research on pain management and palliative care and, in that program, got to know many patients with brain tumors. After that...
  • Ask any patient: Nurses are as pivotal in their care as doctors. They answer the call of a patient in the middle of the night, they hold the patient’s hand as he or she takes on yet another round of treatment and, in the best-case scenario, they wave goodbye as the patient leaves the hospital, […]
  • Many oncologists, not to mention their patients, might think that there’s no place for mathematical analysis in the treatment of cancer. They might think that all treatment decisions are based on unique factors affecting individual patients, with no connection to other patients and their treatment regimen...
  • Within three days in 2007, Stephanie Hosford, then 37, learned that she was pregnant with her long-awaited second child – and that she had triple-negative breast cancer. Soon afterward, Hosford discovered that she and her husband, Grant, had been approved to adopt a little girl from China.  After encountering m...